TAAV Biomanufacturing Solutions
Enzymatic DNA Manufacturing
Enzymatic DNA Manufacturing
neDNA™: Enzymatic DNA for rAAV Manufacturing
We are a CDMO working with biopharma companies, research centers and entities developing programs based on rAAV-based gene therapies.
neDNA™: Discover TAAV manufactured enzymatic DNA

An alternative to plasmids for rAAV manufacturing
We provide the first option for critical starting material for rAAV manufacturing. Designed to transform and accelerate the traditional gene therapy development timelines.
TAAV’s enzymatic DNA is a synthetic, linear, double-stranded, closed-ended molecule which we aim to be the new standard for transfection-based AAV generation.
Our goal
As individuals,
we dream
about future.
As scientists, we have
the chance to make
history.
Together, we have the
power to make it
happen.
Your rAAV manufacturing starts now! We work in a uniquely collaborative industry that can make the world a better place. Let’s make it happen together.
Your rAAV manufacturing starts now. We work in a uniquely collaborative industry that can make the world a better place. Let’s make it happen together.
Led by Science. Inspired by People.
We are a highly innovative
company.
Our solution opens the door to a new area for gene therapy development. This innovation can be only understood by the power of science. But science needs hands. Science needs people committed to the future and passionate to change for better outcomes. We are aimed at changing patients’ lives: this is what inspire us.
We are an innovative life sciences company with the unique purpose of improving people’s lives. This is what inspire us.
Latest news:

What is behind our T?
TAAV started its journey as a company in 2019 and since then, we mantain our essence.

Watch now our session presented at BPI Europe!
At BPI (BioProcess International Europe) our Supply Chain Director, María Dolores Gálvez, presented: “Use of enzymatic

TAAV joins the Basque Health Cluster
We are delighted to have joined the Basque Health Cluster. Following our strategy of continuing to

ISCT Paris 2023
Next week our CEO Dolores Baksh, Ph.D. will be attending ISCT, International Society for Cell &

Life Science Review Interview with our CEO, Dolores Baksh – May 2023
The latest edition of Life Science Review covers our story! There are many clinical trials targeted